Table 1:

Demographic and clinical characteristics of subjects

	CLE n = 226	SLE n = 165	ADM n = 136	AIBD n = 79	Control n = 84
Demographics
Mean Age (s.d.)	48.78 ± 14.60	40.17 ± 13.00	55.44 ± 12.95	65.09 ± 16.10	45 ± 13.96
Female Sex, n (%)	166 (73%)	152 (92%)	123 (90%)	44 (56%)	33 (39%)
Race, n (%)
White	166 (73%)	82 (50%)	127 (93%)	61 (77%)
Black	50 (22%)	68 (41%)	4 (3%)	9 (11%)
Asian	7 (3%)	8 (5%)	4 (3%)	8 (10%)
Other	3 (1%)	7 (4%)	1 (1%)	1 (1%)
Ethnicity, n (%)
Non-Hispanic	218 (96%)	156 (95%)	129 (95%)	79 (100%)
Hispanic	7 (3%)	9 (5%)	3 (2%)	0 (0%)
Unknown	0 (0%)	0 (0%)	4 (3%)	0 (0%)
Current smokers, n (%)	79 (35%)	34 (21%)	8 (6%)	4 (5%)	13 (15%)
Comorbidities, n (%)
HTN	45 (20%)	39 (24%)	26 (21%)	31 (39%)	28 (33%)
Diabetes	6 (3%)	9 (5%)	5 (4%)	11 (14%)	1 (1%)
Hypothyroid disease	25 (11%)	15 (9%)	18 (14%)	9 (11%)
Medications, n (%)
Hydroxychloroquine	124 (55%)	137 (83%)	43 (32%)	0 (0%)	0 (0%)
Chloroquine	14 (6%)	15 (9%)	8 (6%)	0 (0%)	0 (0%)
Quinacrine	44 (19%)	40 (24%)	18 (13%)	0 (0%)	0 (0%)
Methotrexate	31 (14%)	13 (8%)	16 (12%)	1 (1%)	0 (0%)
Azathioprine	25 (11%)	2 (1%)	6 (4%)	2 (3%)	0 (0%)
Thalidomide	9 (4%)	4 (2%)	0 (0%)	0 (0%)	0 (0%)
Mycophenolate Mofetil	37 (16%)	2 (1%)	22 (16%)	14 (18%)	0 (0%)
Prednisone	86 (38%)	21 (13%)	42 (31%)	32 (41%)	0 (0%)
Cyclosporine	0 (0%)	3 (1%)	0 (0%)	0 (0%)	0 (0%)
Rituximab	2 (1%)	0 (0%)	1 (1%)	21 (27%)	0 (0%)
Dapsone	3 (1%)	5 (3%)	1 (1%)	4 (5%)	0 (0%)
IVIG	0 (0%)	0 (0%)	7 (5%)	0 (0%)	0 (0%)
Mean SF-36 mental health score (s.d.)	69.06 ± 20.53	62.90 ± 20.56	68.62 ± 20.86	73.47 ± 21.37

AIBD, autoimmune blistering diseases; ADM, amyopathic dermatomyositis; CLE, cutaneous lupus erythematosus; HTN, hypertension; SLE, systemic lupus erythematosus